The U.S. allergy immunotherapy market size is expected to be valued at US$ 693.4 million in 2026 and projected to reach US$ 1,150.4 million by 2033, growing at a CAGR of 7.5% between 2026 and 2033. Rising allergic disease prevalence across the United States is the primary force behind this growth.

The Centers for Disease Control and Prevention reports that allergic conditions affect a large share of the American population each year. Growing physician preference for disease-modifying immunotherapy over symptomatic treatment, combined with expanding sublingual tablet adoption and rising food allergy diagnoses among children, continues to widen demand for immunotherapy across hospitals, specialty clinics, and home care settings nationwide. Expanding insurance recognition of immunotherapy as a cost-effective long-term treatment option is further reinforcing this steady upward trajectory.

Drivers - Rising Prevalence of Allergic Rhinitis and Asthma Across the U.S.

Allergic disease prevalence continues climbing steadily across the United States. The Centers for Disease Control and Prevention reports that allergic rhinitis affects a substantial share of American adults and children each year. The Asthma and Allergy Foundation of America notes that millions of Americans experience seasonal or perennial allergic rhinitis symptoms severe enough to require ongoing treatment. This growing patient base is prompting physicians to consider immunotherapy earlier in treatment protocols rather than relying solely on antihistamines.

Longer pollen seasons linked to shifting climate patterns are also intensifying allergy symptom severity nationwide. Allergy specialists increasingly view immunotherapy as a long-term disease-modifying option rather than temporary symptom relief. This shift in clinical practice is expanding the addressable patient population for subcutaneous and sublingual immunotherapy products across the country. Growing referral volumes from primary care physicians to board-certified allergists are further reinforcing this expanding treatment funnel.

Expanding FDA Approvals for Sublingual and Oral Immunotherapy Products

Regulatory approvals are broadening the immunotherapy treatment landscape across the United States. The U.S. Food and Drug Administration has approved multiple sublingual immunotherapy tablets for grass, ragweed, and dust mite allergies over the past decade. These tablet-based therapies offer patients a convenient, at-home alternative to traditional injection-based treatment.

The FDA's approval of oral immunotherapy options for peanut allergy has also expanded treatment access for pediatric food allergy patients. Companies such as DBV Technologies continue advancing epicutaneous and oral immunotherapy platforms through the FDA's regulatory pathway. This expanding menu of approved treatment options is encouraging allergists to prescribe immunotherapy more frequently. Broader product availability also strengthens competitive positioning for manufacturers seeking to capture rising domestic demand across multiple allergy types. Continued clinical trial investment by established manufacturers should keep expanding the range of FDA-cleared immunotherapy indications over the coming years.

Market Restraints

Lengthy Treatment Duration Limiting Patient Adherence

Allergy immunotherapy typically requires three to five years of continuous treatment to achieve lasting benefit. This extended commitment discourages many patients from completing their prescribed course. The American Academy of Allergy, Asthma and Immunology has noted that patient dropout remains a persistent challenge within immunotherapy programs.

Frequent clinic visits required for subcutaneous immunotherapy injections add further burden for working patients. This adherence gap limits the overall clinical and commercial impact of immunotherapy, even as awareness of its long-term benefits grows. Reduced completion rates ultimately affect real-world treatment outcomes and future product utilization. Patients living far from specialty clinics face additional scheduling and travel burdens that further compound this adherence challenge.

High Treatment Costs and Inconsistent Insurance Coverage

Allergy immunotherapy involves significant out-of-pocket costs for many patients across the United States. Insurance coverage varies considerably between private payers, Medicare, and Medicaid programs. The Centers for Medicare and Medicaid Services applies specific coverage criteria that can limit patient access to certain immunotherapy formulations. Patients without adequate coverage often face substantial costs for extended treatment courses lasting several years. This financial barrier disproportionately affects lower-income households and rural patients with limited specialist access. Cost concerns continue to slow broader adoption of immunotherapy across some patient populations nationwide. Prior authorization requirements imposed by some insurers can also delay treatment initiation for newly diagnosed patients.

Market Opportunities

Growing Adoption of Sublingual Immunotherapy Tablets in Home Care Settings

Sublingual immunotherapy tablets present a significant growth opportunity for market participants. These tablet-based treatments allow patients to self-administer therapy at home rather than visiting clinics for regular injections. This convenience factor is particularly appealing to time-constrained working adults and parents managing pediatric allergy treatment.

Companies such as ALK-Abelló A/S and Stallergenes Greer have expanded their sublingual tablet portfolios to capture this rising preference. Telehealth-supported allergy consultations are also making it easier for physicians to monitor patients undergoing home-based sublingual treatment. As more patients seek convenient alternatives to weekly injection visits, manufacturers that expand sublingual product lines and strengthen physician education programs stand to capture disproportionate growth. This shift toward home-based care aligns well with broader healthcare trends favoring decentralized treatment delivery across the country. Expanding pharmacy-based dispensing partnerships could further accelerate patient access to these convenient tablet formulations.

Expanding Oral Immunotherapy Access for Pediatric Food Allergy Patients

Food allergy treatment represents a fast-growing opportunity within the U.S. immunotherapy market. The Centers for Disease Control and Prevention reports that food allergy prevalence among American children has risen substantially over the past two decades. This growing patient population is driving demand for oral immunotherapy treatments capable of desensitizing children to common food allergens such as peanuts. DBV Technologies continues developing epicutaneous patch-based immunotherapy platforms targeting pediatric food allergy patients.

Growing parental awareness of oral immunotherapy as a treatment option, supported by pediatric allergist advocacy, is expanding referral volumes to specialty clinics. Companies that invest in pediatric-focused clinical trials and expand physician training programs can capture strong early demand within this expanding segment. Rising school and public awareness of food allergy management also supports sustained long-term growth potential for oral immunotherapy products nationwide. Partnerships with pediatric hospital networks could further accelerate patient identification and referral pathways.

Therapy Type Analysis

Subcutaneous Immunotherapy (SCIT) held the leading position among therapy types, accounting for approximately 43% share of the market in 2025. This leadership reflects SCIT's long clinical track record and broad allergist familiarity across the United States. Subcutaneous injections allow physicians to treat multiple allergens simultaneously within a single treatment protocol, unlike single-allergen sublingual tablets. The American College of Allergy, Asthma and Immunology continues to recognize SCIT as a well-established, evidence-backed treatment option for allergic rhinitis and asthma.

Established reimbursement pathways for SCIT within many insurance plans also support continued physician preference. While Sublingual Immunotherapy is growing faster due to its home-administration convenience, SCIT's broader allergen coverage and established clinical infrastructure keep it the dominant therapy type through the near-term forecast period. Widespread allergist training in SCIT protocols further reinforces its continued clinical preference nationwide.

Allergy Type Analysis

Allergic Rhinitis led the allergy type category, capturing an estimated 39% share of the market in 2025. This leadership stems from its position as the most commonly diagnosed allergic condition across the United States. The Asthma and Allergy Foundation of America reports that allergic rhinitis affects a substantial share of the American population annually, driven by seasonal pollen exposure and indoor allergens such as dust mites.

Physicians frequently recommend immunotherapy for patients with moderate to severe allergic rhinitis symptoms that do not respond adequately to standard antihistamine therapy. Both subcutaneous and sublingual immunotherapy products are widely available and reimbursed for this indication. While Food Allergy treatment is growing rapidly, its smaller current base keeps Allergic Rhinitis the leading allergy type category through the forecast period. Rising diagnosis rates among younger patients should continue reinforcing this segment's broad demand base.

End User Analysis

Specialty Allergy Clinics represented the leading end user category, holding an estimated 48% share of the market in 2025. This dominance reflects the specialized expertise required for allergen testing, immunotherapy formulation, and ongoing patient monitoring. Board-certified allergists operating within dedicated clinics manage the majority of immunotherapy prescriptions across the United States. The American Board of Allergy and Immunology maintains certification standards that support this concentrated referral pattern toward specialty practices.

These clinics also maintain the infrastructure needed to manage rare anaphylactic reactions during in-office immunotherapy administration. While Home Care is growing quickly as sublingual tablet adoption increases, Specialty Allergy Clinics retain leadership due to their central role in diagnosis, treatment initiation, and ongoing clinical oversight throughout the forecast period. Growing clinic network expansion across suburban areas should further reinforce this segment's leadership position.

Northeast Region Allergy Immunotherapy Market Trends and Insights

The Northeast holds a significant share of the U.S. allergy immunotherapy market. Dense urban populations and strong health insurance coverage support broad access to specialty allergy care. Leading academic medical centers across the region conduct extensive immunotherapy research and clinical trials. Seasonal tree and grass pollen exposure drives consistent demand for allergy treatment. Well-established referral networks between primary care physicians and board-certified allergists further support consistent treatment volumes. The region's mature healthcare infrastructure should continue supporting steady, stable growth through the forecast period.

Midwest Region Allergy Immunotherapy Market Trends and Insights

The Midwest represents a steady contributor to the U.S. allergy immunotherapy market. Ragweed pollen exposure during late summer and fall drives significant allergic rhinitis prevalence across the region. Agricultural communities also report elevated rates of environmental allergen exposure. Growing rural telehealth adoption is gradually improving specialist access outside major metropolitan areas. Regional health systems are also expanding satellite allergy clinics to reach smaller communities more effectively. The Midwest's allergy treatment demand should continue growing steadily as awareness of immunotherapy expands further.

West Region Allergy Immunotherapy Market Trends and Insights

The West is projected to register the fastest growth among U.S. regions through 2033. Expanding biotechnology innovation hubs across California support accelerated immunotherapy product development. Rising population growth and expanding specialty clinic networks across the region are strengthening treatment access. Growing telehealth-supported allergy care adoption is also expanding reach into underserved areas. Strong venture capital investment in biotechnology startups across the region continues to accelerate new product development timelines. The West's strong innovation ecosystem positions it for continued above-average growth through the forecast period.

The U.S. allergy immunotherapy market remains moderately consolidated among a group of established international manufacturers. Companies such as ALK-Abelló A/S, Stallergenes Greer, and Merck KGaA compete through broad allergen extract portfolios and established physician relationships. Smaller specialized firms differentiate through novel delivery platforms, including epicutaneous patches and oral immunotherapy formulations.

Market leaders are investing heavily in clinical trials to expand FDA-approved indications across additional allergen types. Digital patient adherence tools and telehealth integration are emerging as differentiating strategies among competitive manufacturers. Strategic partnerships between manufacturers and specialty clinic networks are also becoming more common as companies seek to strengthen distribution across the fragmented U.S. allergy care landscape. Growing investment in pediatric-focused product lines is also emerging as a key competitive differentiator.

Key Developments

• In March 2026, ARS Pharmaceuticals reported US$72.2 million in U.S. net product revenue from neffy® during 2025, marking its first full commercial year. The company also announced that Phase 2b clinical data for its intranasal epinephrine program in chronic spontaneous urticaria (CSU) are expected in mid-2026, supporting expansion of its allergy-focused therapeutic pipeline.
• In March 2025, Results from the Phase III OUtMATCH trial showed that omalizumab (Xolair) was more effective and better tolerated than multi-allergen oral immunotherapy (OIT) in patients with multiple food allergies.